Nan Fung Trinity’s Xenon Pharmaceuticals XENE Stock Holding History

Nan Fung Trinity’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15M	Hold	247,765	–	–	1.48%	29
2026 Q1	$14.4M	Buy	247,765 +20,800	+9%	+$958K	1.58%	26
2025 Q4	$10.2M	Buy	226,965 +68,360	+43%	+$2.87M	0.81%	48
2025 Q3	$6.37M	Hold	158,605	–	–	0.64%	48
2025 Q2	$4.96M	Buy	+158,605	New	+$5.17M	0.59%	47

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Nan Fung Trinity's XENE Position: Q2 2026 in Review

Nan Fung Trinity held its Xenon Pharmaceuticals (XENE) position steady in Q2 2026 at 247,765 shares worth $15M. The position accounts for 1.48% of the portfolio, ranked #29.

Nan Fung Trinity first reported a position in XENE in Q2 2025 and has held it in 5 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Nan Fung Trinity held 247,765 shares of Xenon Pharmaceuticals worth $15M as of Q2 2026.
Nan Fung Trinity left its Xenon Pharmaceuticals share count unchanged in Q2 2026.
Xenon Pharmaceuticals made up 1.48% of Nan Fung Trinity's portfolio in Q2 2026, its #29 holding.
Nan Fung Trinity first reported a position in Xenon Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Nan Fung Trinity's 13F filing for Q2 2026, filed 24 Jul 2026.